Takeda lowers profit outlook amid Vyvanse loss of exclusivity, eyes $900M restructuring in 2024
Takeda saw a 57% drop in profit in its 2023 fiscal year and has lowered its outlook for the coming fiscal year, mostly driven by increasing generic competition for its ADHD treatment Vyvanse.